- Home
- PIII vs CRVO Comparison
PIII vs CRVO Comparison
Compare PIII & CRVO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | PIII | CRVO |
|---|---|---|
| Founded | 2015 | 2001 |
| Country | United States | United States |
| Employees | 320 | N/A |
| Industry | Medical/Nursing Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 37.5M | 39.3M |
| IPO Year | N/A | 2011 |
Fundamental Metrics
Financial Performance| Metric | PIII | CRVO |
|---|---|---|
| Price | $9.86 | $2.78 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 4 | 6 |
| Target Price | $9.00 | ★ $23.00 |
| AVG Volume (30 Days) | 25.2K | ★ 15.7M |
| Earning Date | 05-14-2026 | 05-12-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $4,006,510.00 |
| Revenue This Year | $7.67 | N/A |
| Revenue Next Year | $2.36 | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $1.52 | $2.13 |
| 52 Week High | $16.89 | $13.13 |
Technical Indicators
Market Signals| Indicator | PIII | CRVO |
|---|---|---|
| Relative Strength Index (RSI) | 46.16 | 41.37 |
| Support Level | $9.95 | $2.13 |
| Resistance Level | $12.70 | $4.27 |
| Average True Range (ATR) | 0.85 | 0.27 |
| MACD | -0.09 | -0.07 |
| Stochastic Oscillator | 15.48 | 8.71 |
Price Performance
Historical ComparisonAbout PIII P3 Health Partners Inc.
P3 Health Partners Inc is a patient-centered and physician-led population health management company. P3's model aggregates and supports the community's existing healthcare resources to build a network of community providers working together to deliver coordinated and integrated care to patients with a shared commitment to improving patient outcomes, lowering cost, and delivering experience for all.
About CRVO CervoMed Inc.
CervoMed Inc is a clinical-stage biotechnology company. It is focused on developing treatments for age-related neurologic disorders. The company's product candidate, Neflamapimod, has the potential to treat and improve synaptic dysfunction, the reversible aspect of the underlying disease processes in DLB and certain other neurological disorders.